BullishWhales · Analysts · Analyst Profile
Analyst rating accuracy & track record
Derek Archila does not yet have enough resolved 12-month calls to carry a published score. Check back as their ratings mature.
Ratings & price targets
| Stock | Rating | Price target | Rated | 12-mo vs sector | PT hit |
|---|---|---|---|---|---|
 ARVNArvinas Inc | Buy | $19.00 | May 2025 | +34.6% | Miss |
 IMVTImmunovant Inc | Buy | $45.00 | Dec 2024 | −11.1% | Miss |
 CCCCC4 Therapeutics Inc | Buy | $12.00 | Dec 2024 | −62.9% | Miss |
 SEPNSepterna, Inc. Common Stock | Buy | $43.00 | Nov 2024 | −5.9% | Miss |
 CABACabaletta Bio Inc | Buy | $12.00 | Nov 2024 | −20.3% | Miss |
 KYTXKyverna Therapeutics, Inc. Common Stock | Buy | $24.00 | Nov 2024 | +53.8% | Miss |
 ATYRaTyr Pharma, Inc. | Buy | $17.00 | Oct 2024 | −53.5% | Miss |
 GLUEMonte Rosa Therapeutics Inc | Buy | $17.00 | Aug 2024 | +4.1% | Miss |
| CABACabaletta Bio Inc | Buy | $20.00 | Aug 2024 | −59.1% | Miss |
 ANNXAnnexon Inc | Buy | $10.00 | May 2024 | −49.3% | Miss |
| ANNXAnnexon Inc | Buy | $12.00 | Apr 2024 | −72.8% | Miss |
| ANNXAnnexon Inc | Buy | $12.00 | Mar 2024 | −68.5% | Miss |
 KZRKezar Life Sciences Inc | Buy | $13.00 | May 2023 | −85.7% | Miss |
 ZYMEZymeworks Inc. Common Stock | Buy | $12.00 | Mar 2023 | +10.8% | Hit |
| GLUEMonte Rosa Therapeutics Inc | Buy | $19.00 | Jan 2023 | −29.9% | Miss |
| KZRKezar Life Sciences Inc | Buy | $14.00 | Jan 2023 | −91.2% | Miss |
| KZRKezar Life Sciences Inc | Buy | $17.00 | Jun 2022 | −72.8% | Miss |
| KZRKezar Life Sciences Inc | Buy | $13.00 | May 2022 | −53.5% | Miss |
Go to
Browse the full analyst leaderboardHow analyst accuracy is scored
Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.